Last week, 23andMe, the direct-to-consumer genetic testing service, announced its strategic license agreement with Almirall, a leading global pharmaceutical company, for the rights to a bispecific monoclonal antibody designed to treat Il-36 cytokines in autoimmune and inflammatory diseases. The antibody was discovered by 23andMe’s Therapeutics team, using the genetic information from more than 8 million

Christopher A. Ott, CIPP/US, former Supervisory Counterintelligence and Cyber Counsel to the National Security Division of the U.S. Department of Justice (DOJ), and most recently, a partner in private practice at Davis Wright Tremaine LLP advising clients on litigation and business strategy when facing data and privacy issues, has joined Rothwell Figg’s Privacy, Data